Skip to main
FEMY
FEMY logo

Femasys (FEMY) Stock Forecast & Price Target

Femasys (FEMY) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Femasys Inc. is well-positioned for growth, particularly with the imminent commercialization of FemBloc, as the company has established strong relationships with existing distributors who already market its FemaSeed product. This familiarity with the Femasys brand among customers is expected to drive sales, bolstered by the distributors' commitment to expanding their partnerships to include FemBloc. Furthermore, the potential to begin recognizing sales for FemBloc in Europe as early as the second half of 2025 or the first half of 2026 signals a promising revenue stream that could enhance the company’s financial performance.

Bears say

Femasys Inc faces significant risks that negatively impact its financial outlook, including the possibility of safety signals arising from its clinical and preclinical programs, which could hinder product development. Additionally, the efficacy of its clinical programs may fall short of expectations, and the company may encounter greater competition than anticipated in the marketplace, complicating its commercial viability. Furthermore, the projected need for approximately $60 million in additional financing through 2038 raises concerns about the company's financial health and sustainability, given its estimated cash runway extending only into mid-2025.

Femasys (FEMY) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Femasys and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Femasys (FEMY) Forecast

Analysts have given Femasys (FEMY) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Femasys (FEMY) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Femasys (FEMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.